The EMA’s Safety feature provisions enter into force on 9 February 2019. Member states are required to implement the new Falsified Medicines Safety Features for almost all prescription-only medicines which aim to prevent falsified medicinal products from entering the pharmaceutical supply chain. The safety features are placed on the packaging of the respective medicinal products by the pharmaceutical manufacturer and consist of the following:
a unique identifier, in the form of a 2D data matrix barcode, allowing the verification of the authenticity and the identification of an individual pack of a medicinal product
anti-tampering device
For further details, see the MHRA blog: https://mhrainspectorate.blog.gov.uk/2019/02/08/falsified-medicines-directive-safety-features/
